Medicare would cover qualifying tests to detect Alzheimer’s and related dementias before symptoms or at an early stage, starting January 1, 2028.
Starting January 1, 2028, Medicare would cover qualifying early screening tests for Alzheimer’s and related dementias. Tests must pass federal review, and alternatives to genomic sequencing blood tests need the federal health secretary’s acceptance.
Medicare would cover qualifying tests for early Alzheimer’s and dementia screening. Coverage would include genomic sequencing blood tests and other qualifying tests that detect Alzheimer’s or related dementias before symptoms or at an early stage. Tests must pass a listed Food and Drug Administration review process. Other tests qualify only if the federal health secretary finds that they provide results comparable to genomic sequencing blood tests. The coverage definition applies to tests provided on or after January 1, 2028.
No hearings or votes scheduled.